Table 1.
Overview of studies, registries, and surveys studying drug adherence
| Study | HFrEF patients | % ACEi/ARB | % BB | % MRA | % ARNI | ||||
|---|---|---|---|---|---|---|---|---|---|
| Prescribed | Target dose | Prescribed | Target dose | Prescribed | Target dose | Prescribed | Target dose | ||
| QUALIFY [20] | 7092 | 87.2% | 34.8% | 86.7% | 9.7% | 69.3% | – | – | – |
| BIOSTAT-CHF [21] | 2100 | – | 22% | – | 12% | – | – | – | – |
| ESC HF Long-term Registry [22] | 2834 | 92.6% | 39.5% | 93.3% | 13.2% | 75.5% | 23.5% | – | – |
| Poelzl et al. [23] | 1014 | 90.5% | 38% | 87.8% | 24% | 42.7% | – | – | – |
| TSOC-HFrEF [24] | 1473 | 62% | 5% | 60% | 36% | 49% | 21.6% | – | – |
| Gicc-HF [25] | 275 | 76.3% | 19% | 69% | 10% | – | – | – | – |
| CHAMP-HF [26] | 3518 | 60.5% | 17% | 67% | 28% | 33.4% | 77% | 13% | 14% |
| CHECK-HF [27] | 5701 | 84% | 43.6% | 86% | 18.9% | 56% | 52.0% | – | – |
| Diamant et al. [28] | 370 | 67.3% (86.4%a) | 22.1% (28.6%a) | 88.4% (93.4%a) | 30% (31.7%a) | 38.4% (48.1%a) | 3.2% (4.1%a) | – | – |
aEligble patients without contraindications